Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash.

Abstract

Psoriatic skin lesions associated with anti-tumor necrosis factor (TNF) agents are well-described in the medical literature. However, the etiology and optimal management of this condition remain unclear. Vedolizumab is a novel, gut-specific, anti-integrin agent used for the treatment of inflammatory bowel disease (IBD). We report a case of infliximab-associated psoriasiform lesions in an ulcerative colitis patient. Transition to vedolizumab resulted in resolution of the cutaneous lesions without recurrence and remission of his ulcerative colitis.

• Authors: Ayal Hirsch, Ruben J Colman, Gabriel D Lang, David T Rubin
• Journal: ACG case reports journal (ACG Case Rep J) Vol. 2 Issue 4 Pg. 236-8 (Jul 2015) ISSN: 2326-3253 [Print] United States
• PMID: 26203450 (Publication Type: Case Reports)